NCT04265950View on ClinicalTrials.gov

Establishing Optimal Number of Doses for HPV Vaccination in Children and Adolescents Living With HIV, OPTIMO Trial

PHASE4Active, not recruitingINTERVENTIONAL
Enrollment

97

Participants

Timeline

Start Date

March 10, 2022

Primary Completion Date

June 30, 2026

Study Completion Date

July 31, 2026

Conditions
HIV Infection
Interventions
BIOLOGICAL

Recombinant Human Papillomavirus Nonavalent Vaccine

Given IM

Trial Locations (3)

15001

Via Libre, Lima

21040-360

Evandro Chagas National Institute of Infectious Diseases (INI), Oswaldo Cruz Foundation (FIOCRUZ) STD and AIDS Clinical Research Laboratory, Rio de Janeiro

Unknown

GHESKIO Center, Port-au-Prince

All Listed Sponsors
collaborator

Asociación Civil Via Libre, Peru

OTHER

collaborator

Evandro Chagas National Institute of Infectious Diseases (INI), Oswaldo Cruz Foundation (FIOCRUZ)

UNKNOWN

collaborator

National Cancer Institute (NCI)

NIH

collaborator

GHESKIO Center

UNKNOWN

lead

Fred Hutchinson Cancer Center

OTHER